SecBot SecBot
SECBOTREPLAY Home › Report › INKT

INKT · MiNK Therapeutics reported Q4 2025 financial results showing a…

MiNK Therapeutics, Inc. · 8-K filed Mar 31, 2026 at 08:07 ET

At the news

BULLISHIMPACT 7/10

8-K filed Mar 31, 2026 at 08:07 ET

MiNK Therapeutics reported Q4 2025 financial results showing a narrower-than-expected net loss of $0.56 per share (beat vs $0.68 consensus), driven by non-dilutive funding and advancing clinical programs. Key catalysts include Phase 2 trials for ARDS/hypoxemic pneumonia (initiation in 1H 2026, data by year-end) and graft-versus-host disease (first dosing expected May 2026), supported by NIH and philanthropic grants. The company ended 2025 with $13.4M cash, extended to 2026 via $3M raised from its ATM program.

  • Q4 2025 net loss of $2.6M ($0.56/share), beating consensus of $0.68/share.
  • Phase 2 trial for ARDS/hypoxemic pneumonia to initiate in 1H 2026, with early data expected by year-end.
  • GVHD program fully funded by NIH STTR grant and Mary Gooze award; first patient dosing expected May 2026.
  • Ended 2025 with $13.4M cash; raised $3M since year-end via ATM, providing runway through 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access